Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D19OMU
|
|||
| Drug Name |
PF-06741086
|
|||
| Synonyms |
marstacimab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Hemophilia [ICD-11: 3B10.0; ICD-10: D66-D68; ICD-9: 286] | Phase 3 | [1] | |
| Company |
Pfizer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue factor pathway inhibitor (TFPI) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Panther Pathway | Blood coagulation | |||
| Pathway Interaction Database | Syndecan-4-mediated signaling events | |||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | |||
| WikiPathways | Complement and Coagulation Cascades | |||
| Integrated Breast Cancer Pathway | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03938792) Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B. U.S. National Institutes of Health. | |||
| REF 2 | Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody. AAPS J. 2019 Mar 29;21(3):46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.